Skip to main content

Mottola Frank's Form 4 filing

Supernus Pharmaceuticals, Inc. (SUPN) · filed Dec 22, 2025

Accession no.
0001628280-25-058506
Filed
Dec 22, 2025
Trade date
Dec 19, 2025
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.01M. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mottola FrankCIK 0001804567Officer (SVP, Chief Tech. Ops. Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 19, 2025Common StockMOption exerciseAcquired+5,000$39.40+$197,00020,496Direct
Dec 19, 2025Common StockSSaleDisposed−5,000$50.22−$251,10015,496Direct
Dec 19, 2025Common StockMOption exerciseAcquired+15,000$25.30+$379,50030,496Direct
Dec 19, 2025Common StockSSaleDisposed−15,000$50.47−$757,05015,496Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 19, 2025Common StockMOption exerciseDisposed−5,000$0.00$00Direct
Dec 19, 2025Common StockMOption exerciseDisposed−15,000$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)